Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Kusi, Kwadwo A ^a,b   Faber, Bart W ^a   Riasat, Vanessa ^a,c   Thomas, Alan W ^a   Kocken, Clemens H M ^a   Remarque, Edmond J ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b University of Ghana   (Ghana)

^c HAGA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIVERSITY COVERING PROTEIN 1; DIVERSITY COVERING PROTEIN 2; DIVERSITY COVERING PROTEIN 3; DIVERSITY COVERING PROTEIN MIX VACCINE; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MONTANIDE IMS; MONTANIDE ISA 51; MULTI ALLELE PLASMODIUM FALCIPARUM APICAL MEMBRANE ANTIGEN 1; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VACCINE; APICAL MEMBRANE ANTIGEN I, PLASMODIUM; MEMBRANE PROTEIN; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ALLELE; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN FUNCTION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG MIXTURE; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SPECIFICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; GROWTH INHIBITION; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM FALCIPARUM; RABBIT; SEQUENCE ANALYSIS; AMINO ACID SEQUENCE; ANIMAL; DRUG EFFECT; GENETICS; IMMUNOLOGY; MALARIA FALCIPARUM; METHODOLOGY; MOLECULAR GENETICS; SEQUENCE HOMOLOGY; SPECIES DIFFERENCE;

ORYCTOLAGUS CUNICULUS; PLASMODIUM FALCIPARUM;

ALLELES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; IMMUNITY, HUMORAL; IMMUNIZATION; MALARIA VACCINES; MALARIA, FALCIPARUM; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RABBITS; SEQUENCE HOMOLOGY, AMINO ACID; SPECIES SPECIFICITY;

EID: 78149491347     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015391     Document Type: Article

References (41)

1. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, et al. (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455-467.
2. Noedl H, Socheat D, Satimai W (2009) Artemisinin-resistant malaria in Asia. N Engl J Med 361: 540-541.
3. Van Bortel W, Trung HD, Thuan lK, Sochantha T, Socheat D, et al. (2008) The insecticide resistance status of malaria vectors in the Mekong region.Malar J 7: 102.
4. Aide P, Bassat Q, Alonso PL (2007) Towards an effective malaria vaccine. Arch Dis Child 92: 476-479.
5. Richards JS, Beeson JG (2009) The future for blood-stage vaccines against malaria\. Immunol Cell Biol\ 87\: 377-390.
6. Todryk SM, Hill AV (2007) Malaria vaccines: the stage we are at. Nat Rev Microbiol 5: 487-489.
7. Remarque EJ, Faber BW, Kocken CH, Thomas AW (2008) Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 24: 74-84.
8. Barclay VC, Chan BH, Anders RF, Read AF (2008) Mixed allele malaria vaccines: host protection and within-host selection. Vaccine 26: 6099-6107.
9. Crewther PE, Matthew ML, Flegg RH, Anders RF (1996) Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect Immun 64: 3310-3317.
10. Polley SD, Conway DJ (2001) Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene. Genetics 158: 1505-1512.
11. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, et al. (2009) Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A. PLoS ONE 4: e5254.
12. Cortes A, Mellombo M, Masciantonio R, Murphy VJ, Reeder JC, et al. (2005) Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1. Infect Immun 73: 422-430.
13. Hodder AN, Crewther PE, Anders RF (2001) Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 69: 3286-3294.
14. Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, et al. (2004) Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23: 718-728.
15. Kusi KA, Faber BW, Thomas AW, Remarque EJ (2009) Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. PLoS ONE 4: e8110.
16. Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, et al. (2002) In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 70: 6948-6960.
17. Mullen GE, Ellis RD, Miura K, Malkin E, Nolan C, et al. (2008) Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS ONE 3: e2940.
18. Remarque EJ, Faber BW, Kocken CH, Thomas AW (2008) A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun 76: 2660-2670.
19. Hui GS, Hashimoto CN (2008) Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment. Int Immunopharmacol 8: 1012-1022.
20. Rawlings DJ, Kaslow DC (1992) Adjuvant-dependent immune response to malarial transmission-blocking vaccine candidate antigens. J Exp Med 176: 1483-1487.
21. Faber BW, Remarque EJ, Kocken CH, Cheront P, Cingolani D, et al. (2008) Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris. Vaccine.
22. Blom AG, Hilgers LAT (2004) Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition. Vaccine 23: 743-754.
23. Aucouturier J, Ascarateil S, Dupuis L (2006) The use of oil adjuvants in therapeutic vaccines. Vaccine 24: S44-S45.
24. Bonhoure F, Gaucheron J (2006) Montanide ISA 51 VG as Adjuvant for Human Vaccines. Journal of Immunotherapy 29.
25. Aucouturier J, Ganne V, Laval A (2000) Efficacy and safety of new adjuvants. Ann N Y Acad Sci 916: 600-604.
26. Dutta S, Lee SY, Batchelor AH, Lanar DE (2007) Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci U S A 104: 12488-12493.
27. Miura K, Zhou H, Muratova OV, Orcutt AC, Giersing B, et al. (2007) In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized. Infect Immun 75: 5827-5836.
28. Doolan DL, Dobano C, Baird JK (2009) Acquired Immunity to Malaria. Clinical Microbiology Reviews 22: 13-36.
29. Howell SA, Withers-Martinez C, Kocken CH, Thomas AW, Blackman MJ (2001) Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1. J Biol Chem 276: 31311-31320.
30. Narum DL, Thomas AW (1994) Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol Biochem Parasitol 67: 59-68.
31. Coley AM, Parisi K, Masciantonio R, Hoeck J, Casey JL, et al. (2006) The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody. Infect Immun 74: 2628-2636.
32. Collins CR, Withers-Martinez C, Hackett F, Blackman MJ (2009) An inhibitory antibody blocks interactions between components of the malarial invasion machinery. PLoS Pathog 5: e1000273.
33. Andersen PH, Nielsen M, Lund O (2006) Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci 15: 2558-2567.
34. Collins WE, Pye D, Crewther PE, Vandenberg KL, Galland GG, et al. (1994) Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg 51: 711-719.
35. Dubois P, Pereira dS (1995) Towards a vaccine against asexual blood stage infection by Plasmodium falciparum. Res Immunol 146: 263-275.
36. Gatton ML, Cheng Q (2004) Investigating antigenic variation and other parasite-host interactions in Plasmodium falciparum infections in naive hosts. Parasitology 128: 367-376.
37. Good MF (2005) Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol 21: 29-34.
38. Struik SS, Riley EM (2004) Does malaria suffer from lack of memory? Immunol Rev 201: 268-290.
39. Hui G, Choe D, Hashimoto C (2008) Biological activities of anti-merozoite surface protein-1 antibodies induced by adjuvant-assisted immunizations in mice with different immune gene knockouts. Clin Vaccine Immunol 15: 1145-1150.
40. Hui GS, Chang SP, Gibson H, Hashimoto A, Hashiro C, et al. (1991) Influence of adjuvants on the antibody specificity to the Plasmodium falciparum major merozoite surface protein, gp195. J Immunol 147: 3935-3941.
41. Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, et al. (2009) High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS ONE 4: e8138.